References
- Schreckenberger PC, Daneshvar MI, Weyant RS, Hollis DG. Acinetobacter, Achromobacter, Moraxella, and other non-fermentative Gram-negative rods. Manual of clinical microbiology, PR Murray, JE Baron, JH Jorgensen, MA Pfaller, RH Yolken. ASM Press, Washington D.C 2003; 749–79
- Yabuuchi E, Oyama A. Achromobacter xylosoxidans n. sp. from human ear discharge. Jpn J Microbiol 1971; 15: 477–81
- Duggan JM, Goldstein SJ, Chenoweth CE, Kauffman CA, Bradley SF. Achromobacter xylosoxidans bacteraemia: report of 4 cases and review of the literature. Clin Infect Dis 1996; 23: 569–76
- Tena D, Carranza R, Barberá JR, Valdezate S, Garrancho JM, Arranz M, et al. Outbreak of long-term intravascular catheter-related bacteraemia due to Achromobacter xylosoxidans subspecies xylosoxidans in a haemodialysis unit. Eur J Clin Microbiol Infect Dis 2005; 24: 727–32
- National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard. NCCLS document M7-A3. Villanova, Pennsylvania: National Committee for Clinical Laboratory Standards, 2003.
- Garner JS, Jarvis R, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections. Am J Infect Control 1988; 16: 128–40
- Igra-Siegman Y, Chmel H, Cobbs C. Clinical and laboratory characteristics of Achromobacter xylosoxidans infection. J Clin Microbiol 1980; 11: 141–5
- Cieslak TJ, Raszka WV. Catheter-associated sepsis due to Alcaligenes xylosoxidans in a child with AIDS. Clin Infect Dis 1993; 16: 592–3
- Reina J, Antich M, Siquier B, Alomar P. Nosocomial outbreak of Achromobacter xylosoxidans associated with a diagnostic contrast solution. J Clin Pathol 1988; 41: 920–3
- Gahrn-Hansen B, Alstrup P, Dessau R, Fursted K, Knudsen A, Olsen H, et al. Outbreak of infection with Achromobacter xylosoxidans from contaminated intravascular pressure transducers. J Hosp Infect 1988; 12: 1–6
- Aisenberg G, Rolston KV, Safdar A. Bacteraemia caused by Achromobacter and Alcaligenes species in 46 patients with cancer (1989–2003). Cancer 2004; 101: 2134–40
- Shie SS, Huang CT, Leu HS. Characteristics of Achromobacter xylosoxidans bacteraemia in northern Taiwan. J Microbiol Immunol Infect 2005; 38: 277–82
- van Horn K, Gedris CA, Ahmed T, Wormser GP. Bacteraemia and urinary tract infection associated with CDC Group vd biovar 2. J Clin Microbiol 1989; 27: 201–2
- Reverdy ME, Freney J, Fleurette J, Coulet M, Surgot M, Marmet D, et al. Nosocomial colonization and infection by Achromobacter xylosoxidans. J Clin Microbiol 1984; 19: 140–3
- Fass RJ, Barnishan J, Solomon MC, Ayers LW. In vitro activities of quinolones, β-lactams, tobramycin, and trimethoprim-sulfamethoxazole against non-fermentative Gram-negative bacilli. J Clin Microbiol 1996; 40: 1412–8
- Senda K, Arakawa Y, Ichiyama S, Nakashima K, Ito H, Ohsuka S, et al. PCR detection of metallo-beta-lactamase gene (blaIMP) in Gram-negative rods resistant to broad-spectrum beta-lactams. J Clin Microbiol 1996; 34: 2909–13
- Saiman L, Chen Y, Gabriel PS, Knirsch C. Synergistic activities of macrolide antibiotics against Pseudomonas aeruginosa, Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans isolated from patients with cystic fibrosis. Antimicrob Agents Chemother 2002; 46: 1105–7